首页> 外国专利> THERAPEUTIC APPLICATION OF ISOLATED NATURALLY-OCCURRING SOLUBLE TRUNCATED FORMS OF IL-23 RECEPTOR

THERAPEUTIC APPLICATION OF ISOLATED NATURALLY-OCCURRING SOLUBLE TRUNCATED FORMS OF IL-23 RECEPTOR

机译:IL-23受体天然可溶截短形式的治疗学应用

摘要

The present invention relates to an isolated naturally-occurring soluble truncated IL-23Rα protein, which is a translated protein resulting from a mRNA splice variant of IL-23Rα. The soluble IL-23Rα proteins (e.g., Δ9 and Δ8,9) represents a novel soluble IL-23Rα protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that Δ9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23Rα protein. More importantly, the present invention provides an utility application of the Δ9 and Δ8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, Δ9 and Δ8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of Δ9 and Δ8,9 in treating a human patient inflicted with Crohn's disease.
机译:本发明涉及分离的天然存在的可溶性截短的IL-23Rα蛋白,其是由IL-23Rα的mRNA剪接变体产生的翻译蛋白。可溶性IL-23Rα蛋白(例如Δ9和Δ8,9)代表一种新型的可溶性IL-23Rα蛋白,该蛋白缺少跨膜结构域,在其C末端具有唯一的八(8)个氨基酸(GLKEGSYC)(由于移码)。 ELISA显示Δ9存在于血液中,可作为包括克罗恩氏病在内的自身免疫疾病的诊断工具。还提供了重组生产这种可溶性截短形式的IL-23Rα蛋白的方法。更重要的是,本发明提供了Δ9和Δ8,9蛋白在抑制IL-23R介导的细胞信号转导中的实用应用。更特别地,Δ9和Δ8,9阻止STAT3的形成以及Th17的成熟。提供了Δ9和Δ8,9在治疗患有克罗恩氏病的人类患者中的治疗应用。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号